Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System

Study acronym: BRAF SENS
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fields
  2. Study First Submitted
The goal of this prospective, low-interventional study is to develop and optimize a highly sensitive and specific method for the detection of the BRAF V600E mutation in liquid biopsy samples from patients with unresectable metastatic melanoma after disease relapse. The method will be based on a CRISPR/Cas12a system combined with isothermal amplification and endpoint electrochemical detection using electrode chips and low-cost instrumentation.
Trial Details
NCT Number NCT07870265
Lead Sponsor Masaryk Memorial Cancer Institute
Conditions
(from sponsor)		 Unresectable Metastatic Melanoma
Related terms Melanoma
Enrollment 17 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov